In January, Medicare launched a prescription-drug program, which now provides coverage to about 22 million Americans. Since it buys medications for that many people, it should get a really good price – probably the lowest price possible – for the drugs it buys. But this isn’t what happens. Instead, the program’s structure prevents Medicare from obtaining the best possible prices for prescription drugs, even though high drug costs were the impetus for the benefit in the first place.
Read more here.